Temporal and spatial progression of microstructural cerebral degeneration in ALS: A multicentre longitudinal diffusion tensor imaging study.

Amyotrophic Lateral Sclerosis DTI Diffusion tensor imaging MRI Magnetic resonance imaging Motor cortex Multicentre study

Journal

NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070

Informations de publication

Date de publication:
14 Jun 2024
Historique:
received: 04 10 2023
revised: 12 06 2024
accepted: 13 06 2024
medline: 19 6 2024
pubmed: 19 6 2024
entrez: 18 6 2024
Statut: aheadofprint

Résumé

The corticospinal tract (CST) reveals progressive microstructural alterations in ALS measurable by DTI. The aim of this study was to evaluate fractional anisotropy (FA) along the CST as a longitudinal marker of disease progression in ALS. The study cohort consisted of 114 patients with ALS and 110 healthy controls from the second prospective, longitudinal, multicentre study of the Canadian ALS Neuroimaging Consortium (CALSNIC-2). DTI and clinical data from a harmonized protocol across 7 centres were collected. Thirty-nine ALS patients and 61 controls completed baseline and two follow-up visits and were included for longitudinal analyses. Whole brain-based spatial statistics and hypothesis-guided tract-of-interest analyses were performed for cross-sectional and longitudinal analyses. FA was reduced at baseline and longitudinally in the CST, mid-corpus callosum (CC), frontal lobe, and other ALS-related tracts, with alterations most evident in the CST and mid-CC. CST and pontine FA correlated with functional impairment (ALSFRS-R), upper motor neuron function, and clinical disease progression rate. Reduction in FA was largely located in the upper CST; however, the longitudinal decline was greatest in the lower CST. Effect sizes were dependent on region, resulting in study group sizes between 17 and 31 per group over a 9-month interval. Cross-sectional effect sizes were maximal in the upper CST; whereas, longitudinal effect sizes were maximal in mid-callosal tracts. Progressive microstructural alterations in ALS are most prominent in the CST and CC. DTI can provide a biomarker of cerebral degeneration in ALS, with longitudinal changes in white matter demonstrable over a reasonable observation period, with a feasible number of participants, and within a multicentre framework.

Identifiants

pubmed: 38889523
pii: S2213-1582(24)00072-X
doi: 10.1016/j.nicl.2024.103633
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103633

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Hans-Peter Müller (HP)

Department of Neurology, University of Ulm, Ulm, Germany. Electronic address: hans-peter.mueller@uni-ulm.de.

Agessandro Abrahao (A)

Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Christian Beaulieu (C)

Department of Biomedical Engineering, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada.

Michael Benatar (M)

Neuromuscular Division, Department of Neurology, University of Miami, Miami, FL, United States.

Annie Dionne (A)

Department of Medicine, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada.

Angela Genge (A)

Department of Neurology, McGill University, Montreal, Quebec, Canada.

Richard Frayne (R)

Departments of Radiology and Clinical Neuroscience, Hotchkiss Brain Institute, University of Calgary, Alberta, Canada.

Simon J Graham (SJ)

Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Summer Gibson (S)

Neuromuscular Medicine Division, University of Utah, Salt Lake City, Utah, United States.

Lawrence Korngut (L)

Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada.

Collin Luk (C)

Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada; Divison of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Robert C Welsh (RC)

Department of Psychiatry and Biobehavioral Science, UCLA, Los Angeles, CA, United States.

Lorne Zinman (L)

Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Jan Kassubek (J)

Department of Neurology, University of Ulm, Ulm, Germany; German Centre of Neurodegenerative Diseases (DZNE), Ulm, Germany.

Sanjay Kalra (S)

Department of Biomedical Engineering, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada; Divison of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada. Electronic address: sanjay.kalra@ualberta.ca.

Classifications MeSH